NCT02788656 - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 9, 2018

Study Completion Date

November 9, 2018

Conditions

Congestive Heart Failure

Interventions

DEVICE

Implantable Hemodynamic Monitor

The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.

DRUG

Angiotensin-Converting Enzyme Inhibitor

Conventional, guideline-directed therapy for heart failure and reduced ejection fraction

DRUG

Angiotensin II Type 1 Receptor Blocker

Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients

DRUG

sacubitril/valsartan

Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker

Trial Locations (1)

02115

Brigham and Women's Hospita, Boston